Building the world’s largest biobank with data from global populations to accelerate biomarker and drug discovery and ...
ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders – – Topline Data Expected Mid-Year 2025 – MELBOURNE, ...
Creatv Bio, a Division of Creatv MicroTech, Inc. (Creatv) will be collaborating with CytoDyn Therapeutics Corporation (CytoDyn) to assess patient response to their drug using the LifeTracDx® blood ...
The Global Single-cell Analysis Market is projected to grow at a CAGR of 9.5% from 2026 to 2033, according to a new report ...
Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death of a patient taking Sarepta’s Elevidys raises important safety questions.
Varied approaches to remote patient monitoring are in development to close care gaps between patients and rheumatologists, ...
23hon MSN
A research team has developed an innovative technique that enables precise modification of specific proteins within complex ...
Trump’s administration this week abruptly terminated funding for a slew of studies designed to learn how to better treat the ...
Presented a poster highlighting the use of the Company's Magellan™ drug discovery platform to identify allosteric inhibitors ...
Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for ...
Eli Lilly and Company (LLY) has expanded its LillyDirect digital healthcare platform to offer connections to independent in-person and telehealth options for people in the U.S. living with Alzheimer's ...
JP Morgan's survey of endocrinologists finds strong awareness of Crinetics' atumelnant, with positive efficacy impressions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback